Drug Profile
Teriparatide intranasal - Critical Pharmaceuticals
Alternative Names: CP-046; CP046 PTH CriticalSorbLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Critical Pharmaceuticals
- Developer Critical Pharmaceuticals; University of Nottingham
- Class Diagnostic agents; Osteoporosis therapies; Peptide hormones; Skin disorder therapies
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Osteoporosis(In volunteers) in United Kingdom (Intranasal, Spray)
- 15 Apr 2014 Phase-I clinical trials in Osteoporosis (in volunteers) in United Kingdom (Intranasal)
- 21 Nov 2013 Preclinical trials in Osteoporosis in United Kingdom (Intranasal)